DK3683220T3 - 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropylimidazo[4,5-c]quinolin-2-on-derivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af huntingtons sygdom - Google Patents

8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropylimidazo[4,5-c]quinolin-2-on-derivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af huntingtons sygdom Download PDF

Info

Publication number
DK3683220T3
DK3683220T3 DK20156172.7T DK20156172T DK3683220T3 DK 3683220 T3 DK3683220 T3 DK 3683220T3 DK 20156172 T DK20156172 T DK 20156172T DK 3683220 T3 DK3683220 T3 DK 3683220T3
Authority
DK
Denmark
Prior art keywords
isopropylimidazo
muttered
quinolin
propoxy
pyridyl
Prior art date
Application number
DK20156172.7T
Other languages
Danish (da)
English (en)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Thomas Anthony Hunt
Andrew John Eatherton
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3683220T3 publication Critical patent/DK3683220T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK20156172.7T 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropylimidazo[4,5-c]quinolin-2-on-derivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af huntingtons sygdom DK3683220T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1516504.6A GB201516504D0 (en) 2015-09-17 2015-09-17 Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
EP16770461.8A EP3350180B1 (en) 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3683220T3 true DK3683220T3 (da) 2022-07-04

Family

ID=54544418

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20156172.7T DK3683220T3 (da) 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropylimidazo[4,5-c]quinolin-2-on-derivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af huntingtons sygdom
DK16770461.8T DK3350180T3 (da) 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-onderivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16770461.8T DK3350180T3 (da) 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-onderivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af cancer

Country Status (37)

Country Link
US (5) US9856255B2 (enExample)
EP (2) EP3350180B1 (enExample)
JP (1) JP6605130B2 (enExample)
KR (2) KR102028848B1 (enExample)
CN (1) CN108137576B (enExample)
AR (1) AR106053A1 (enExample)
AU (1) AU2016323399B2 (enExample)
BR (1) BR112018004325B1 (enExample)
CA (1) CA2997399C (enExample)
CL (1) CL2018000677A1 (enExample)
CO (1) CO2018002829A2 (enExample)
CR (1) CR20180172A (enExample)
CY (1) CY1124680T1 (enExample)
DK (2) DK3683220T3 (enExample)
DO (1) DOP2018000065A (enExample)
EA (1) EA033284B1 (enExample)
ES (2) ES2920876T3 (enExample)
GB (1) GB201516504D0 (enExample)
HR (1) HRP20210149T1 (enExample)
HU (2) HUE053066T2 (enExample)
IL (1) IL257847B (enExample)
LT (1) LT3350180T (enExample)
MX (1) MX384930B (enExample)
MY (2) MY195669A (enExample)
NI (1) NI201800033A (enExample)
PE (1) PE20181078A1 (enExample)
PH (1) PH12018500532A1 (enExample)
PL (2) PL3350180T3 (enExample)
PT (2) PT3683220T (enExample)
RS (1) RS61435B1 (enExample)
SI (1) SI3350180T1 (enExample)
SM (1) SMT202100071T1 (enExample)
SV (1) SV2018005655A (enExample)
TN (1) TN2018000078A1 (enExample)
TW (2) TWI762109B (enExample)
WO (1) WO2017046216A1 (enExample)
ZA (1) ZA202209171B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
AU2019339006B2 (en) * 2018-09-14 2024-03-14 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo (4, 5-c) cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
EP4115883A4 (en) * 2020-03-04 2024-04-10 Pharos Ibio Co., Ltd. USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, MITIGATING OR TREATING OVARIAN CANCER
CN116194109A (zh) * 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
CN116322699B (zh) * 2020-09-28 2025-02-11 石药集团中奇制药技术（石家庄）有限公司 一类并环化合物及其制备和应用
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022125614A1 (en) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates as inhibitors of enpp1 and cdnp
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) * 2021-08-25 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 一种杂环类化合物及其制备方法和用途
GB202114704D0 (en) 2021-10-14 2021-12-01 Univ Birmingham ATM inhibition
AU2023212227A1 (en) * 2022-01-26 2024-08-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Hydrazino group-containing compound
CN118984706A (zh) * 2022-04-11 2024-11-19 钟卫 一种取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮衍生物的晶型、其盐的晶型、制备方法及应用
TW202446421A (zh) 2023-04-10 2024-12-01 日商第一三共股份有限公司 抗ｂ７－ｈ３抗體－藥物結合物與ａｔｒ抑制劑或ａｔｍ抑制劑之組合
TW202529760A (zh) 2023-09-13 2025-08-01 瑞典商阿斯特捷利康公司 治療方法
TW202535383A (zh) 2024-03-13 2025-09-16 瑞典商阿斯特捷利康公司 治療方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094139A1 (en) 1990-10-22 1992-04-23 Frederick W. Wassmundt Aryl and heteroaryl compounds having anti-retrovirus activity
TW301607B (enExample) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
EP1107759A1 (en) 1998-08-03 2001-06-20 Basf Corporation Pyridinones for the treatment of sexual dysfunction
CA2362401A1 (en) 1999-02-04 2000-08-10 Paul Fleming G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002303156A1 (en) 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
JP2005520171A (ja) 2001-04-10 2005-07-07 トランス　テック　ファーマ，インコーポレイテッド ドラッグディスカバリーに関する、プローブ、システム、および方法
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
JP4082888B2 (ja) 2001-10-17 2008-04-30 広栄化学工業株式会社 ビアリール化合物の製造法
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
EP1542948A4 (en) 2002-08-23 2008-12-17 Univ Connecticut NEW BIPHENYL AND BIPHENYLENE CANNABINOIDS
US7183313B2 (en) 2002-08-23 2007-02-27 University Of Connecticut Keto cannabinoids with therapeutic indications
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
EP1604971A4 (en) 2003-03-11 2006-08-16 Ono Pharmaceutical Co CINEMA ALCOHOL DERIVATIVES AND MEDICAMENTS CONTAINING THE COMPOUNDS AS AN ACTIVE SUBSTANCE
WO2004113258A1 (ja) 2003-06-20 2004-12-29 Shionogi & Co., Ltd. 炭素−炭素結合生成反応
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
ATE400573T1 (de) 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
PL1826197T3 (pl) 2004-12-13 2012-06-29 Ono Pharmaceutical Co Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070032522A1 (en) 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
EP1962861A2 (en) 2005-08-26 2008-09-03 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
WO2008103636A1 (en) 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
CA2717948C (en) 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
EP2356120B1 (en) 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US20120093917A1 (en) 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2763821A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
CN102803259A (zh) * 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
KR101449217B1 (ko) 2009-09-28 2014-10-08 에프. 호프만-라 로슈 아게 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012025213A2 (en) 2010-08-23 2012-03-01 Grünenthal GmbH Novel therapeutic compounds
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
AR083267A1 (es) 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
US20130245061A1 (en) 2010-12-03 2013-09-19 Novartis Ag Pharmaceutical compositions
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
JO3003B1 (ar) * 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2726465A1 (en) 2011-05-23 2014-05-07 Elan Pharmaceuticals Inc. Inhibitors of lrrk2 kinase activity
CA2837312A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
EP2776437B1 (en) 2011-11-07 2018-09-26 Sunovion Pharmaceuticals Inc. Modulators of opioid receptors and methods of use thereof
WO2013074965A1 (en) 2011-11-16 2013-05-23 Microbiotix, Inc. Aminoalkyl phenol ether inhibitors of influenza a virus
WO2013157018A1 (en) 2012-04-18 2013-10-24 Indian Institute Of Technology Madras A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
BR112014030099A2 (pt) 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
EP2861580B1 (en) 2012-06-07 2018-04-25 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
IN2015DN00528A (enExample) 2012-08-16 2015-06-26 Novartis Ag
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
KR20150125665A (ko) 2013-03-12 2015-11-09 큐어제닉스 인크. 암 치료용 화합물
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
WO2015073804A2 (en) 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
JP2016540773A (ja) * 2013-12-06 2016-12-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
PT3560924T (pt) 2015-04-02 2021-07-02 Merck Patent Gmbh Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
US10858316B2 (en) 2015-07-10 2020-12-08 University Of Maryland, Baltimore Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso

Also Published As

Publication number Publication date
TW202124381A (zh) 2021-07-01
CY1124680T1 (el) 2022-07-22
DOP2018000065A (es) 2018-03-30
CN108137576B (zh) 2020-09-22
SV2018005655A (es) 2018-04-27
ES2853924T3 (es) 2021-09-20
KR20190112852A (ko) 2019-10-07
JP6605130B2 (ja) 2019-11-13
ZA202209171B (en) 2023-11-29
EP3350180A1 (en) 2018-07-25
HK1257413A1 (en) 2019-10-18
TWI714631B (zh) 2021-01-01
JP2018531226A (ja) 2018-10-25
SMT202100071T1 (it) 2021-03-15
HUE053066T2 (hu) 2021-06-28
US11613539B2 (en) 2023-03-28
US10882858B2 (en) 2021-01-05
IL257847A (en) 2018-04-30
HUE058884T2 (hu) 2022-09-28
CA2997399A1 (en) 2017-03-23
CN108137576A (zh) 2018-06-08
IL257847B (en) 2020-08-31
US20210147416A1 (en) 2021-05-20
AR106053A1 (es) 2017-12-06
US9856255B2 (en) 2018-01-02
CL2018000677A1 (es) 2018-08-17
MX2018003186A (es) 2018-05-17
ES2920876T3 (es) 2022-08-11
RS61435B1 (sr) 2021-03-31
DK3350180T3 (da) 2021-02-15
KR20180052724A (ko) 2018-05-18
US20170081325A1 (en) 2017-03-23
EP3683220A1 (en) 2020-07-22
US20230286981A1 (en) 2023-09-14
TN2018000078A1 (en) 2019-07-08
CO2018002829A2 (es) 2018-05-31
AU2016323399A1 (en) 2018-05-10
PH12018500532A1 (en) 2018-08-29
MY198813A (en) 2023-09-29
US10457679B2 (en) 2019-10-29
CA2997399C (en) 2024-02-20
SI3350180T1 (sl) 2021-03-31
PE20181078A1 (es) 2018-07-05
PL3683220T3 (pl) 2022-08-01
MX384930B (es) 2025-03-14
PL3350180T3 (pl) 2021-05-17
EP3350180B1 (en) 2020-11-11
EP3683220B1 (en) 2022-04-13
TWI762109B (zh) 2022-04-21
MY195669A (en) 2023-02-03
GB201516504D0 (en) 2015-11-04
PT3683220T (pt) 2022-06-24
EA033284B1 (ru) 2019-09-30
US20180141943A1 (en) 2018-05-24
LT3350180T (lt) 2021-02-25
BR112018004325A2 (enExample) 2018-10-02
HK1255408A1 (zh) 2019-08-16
AU2016323399B2 (en) 2019-04-18
NZ741661A (en) 2024-04-26
TW201722946A (zh) 2017-07-01
BR112018004325B1 (pt) 2023-10-17
CR20180172A (es) 2018-05-25
EA201890650A1 (ru) 2018-10-31
WO2017046216A1 (en) 2017-03-23
NI201800033A (es) 2018-10-18
US20200102302A1 (en) 2020-04-02
PT3350180T (pt) 2021-02-08
HRP20210149T1 (hr) 2021-03-19
KR102028848B1 (ko) 2019-10-04
KR102469153B1 (ko) 2022-11-22

Similar Documents

Publication Publication Date Title
DK3683220T3 (da) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropylimidazo[4,5-c]quinolin-2-on-derivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af huntingtons sygdom
IL262304A (en) Methods for providing single-stranded rna
IL264142A (en) Multispecific antibodies against cd40 and cd137
DK3516060T3 (da) Antisense-oligonukleotider til behandling af øjensygdom
DK3365334T3 (da) Benzolactamforbindelser som proteinkinaseinhibitorer
EP3503850A4 (en) HUMERAL HEAD IMPLANT SYSTEM
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3292137T3 (da) Proteiner specifikke for cd137
ME03432B (me) Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3288940T5 (da) Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
DK3242666T3 (da) Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
EP3350072A4 (en) ADJUSTABLE FLOW SYSTEM
EP3412564A4 (en) AIRCRAFT, PLANE AND CONTROL PROCEDURE
DK3294769T3 (da) Behandling for multipelt myelom (mm)
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
DK3670499T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3345581T3 (da) Elektrisk understøttet kørestol samt fremgangsmåde til styring af den elektrisk understøttede kørestol
DK3110425T3 (da) Ikke-flygtig ophthalmisk sammensætning, især til behandling af tør-øje-syndrom
LT3500572T (lt) Citizino dariniai, skirti priklausomybių gydymui
DK3493673T3 (da) Fremgangsmåde til bekæmpelse af coccidiose hos fjerkræ